Cargando…

Apolipoproteins A-I and B: biosynthesis, role in the development of atherosclerosis and targets for intervention against cardiovascular disease

Apolipoprotein (apo) AI and apoB are the major apolipoproteins of high-density lipoprotein (HDL) and low-density lipoprotein (LDL), respectively. ApoB assembles the precursor of LDL, very-low-density lipoprotein (VLDL), in the liver. The assembly starts with the formation of a primordial particle, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Olofsson, Sven-Olof, Wiklund, Olov, Borén, Jan
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2291326/
https://www.ncbi.nlm.nih.gov/pubmed/17969379
_version_ 1782152446262378496
author Olofsson, Sven-Olof
Wiklund, Olov
Borén, Jan
author_facet Olofsson, Sven-Olof
Wiklund, Olov
Borén, Jan
author_sort Olofsson, Sven-Olof
collection PubMed
description Apolipoprotein (apo) AI and apoB are the major apolipoproteins of high-density lipoprotein (HDL) and low-density lipoprotein (LDL), respectively. ApoB assembles the precursor of LDL, very-low-density lipoprotein (VLDL), in the liver. The assembly starts with the formation of a primordial particle, which is converted to VLDL2. The VLDL2 particle is then transferred to the Golgi apparatus and can either be secreted or converted to triglyceride-rich VLDL1. We have reviewed this assembly process, the process involved in the storage of triglycerides in cytosolic lipid droplets, and the relationship between these two processes. We also briefly discuss the formation of HDL. ApoB mediates the interaction between LDL and the arterial wall. Two regions in apoB are involved in this binding. This interaction and its role in the development of atherosclerosis are reviewed. ApoB can be used to measure the number of LDL or VLDL particles present in plasma, as there is one molecule of apoB on each particle. By contrast, the amount of cholesterol and other lipids on each particle varies under different conditions. We address the possibility of using apoAI and apoB levels to estimate the risk of development of cardiovascular diseases and to monitor intervention to treat these diseases.
format Text
id pubmed-2291326
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-22913262008-04-22 Apolipoproteins A-I and B: biosynthesis, role in the development of atherosclerosis and targets for intervention against cardiovascular disease Olofsson, Sven-Olof Wiklund, Olov Borén, Jan Vasc Health Risk Manag Review Apolipoprotein (apo) AI and apoB are the major apolipoproteins of high-density lipoprotein (HDL) and low-density lipoprotein (LDL), respectively. ApoB assembles the precursor of LDL, very-low-density lipoprotein (VLDL), in the liver. The assembly starts with the formation of a primordial particle, which is converted to VLDL2. The VLDL2 particle is then transferred to the Golgi apparatus and can either be secreted or converted to triglyceride-rich VLDL1. We have reviewed this assembly process, the process involved in the storage of triglycerides in cytosolic lipid droplets, and the relationship between these two processes. We also briefly discuss the formation of HDL. ApoB mediates the interaction between LDL and the arterial wall. Two regions in apoB are involved in this binding. This interaction and its role in the development of atherosclerosis are reviewed. ApoB can be used to measure the number of LDL or VLDL particles present in plasma, as there is one molecule of apoB on each particle. By contrast, the amount of cholesterol and other lipids on each particle varies under different conditions. We address the possibility of using apoAI and apoB levels to estimate the risk of development of cardiovascular diseases and to monitor intervention to treat these diseases. Dove Medical Press 2007-08 /pmc/articles/PMC2291326/ /pubmed/17969379 Text en © 2007 Dove Medical Press Limited. All rights reserved
spellingShingle Review
Olofsson, Sven-Olof
Wiklund, Olov
Borén, Jan
Apolipoproteins A-I and B: biosynthesis, role in the development of atherosclerosis and targets for intervention against cardiovascular disease
title Apolipoproteins A-I and B: biosynthesis, role in the development of atherosclerosis and targets for intervention against cardiovascular disease
title_full Apolipoproteins A-I and B: biosynthesis, role in the development of atherosclerosis and targets for intervention against cardiovascular disease
title_fullStr Apolipoproteins A-I and B: biosynthesis, role in the development of atherosclerosis and targets for intervention against cardiovascular disease
title_full_unstemmed Apolipoproteins A-I and B: biosynthesis, role in the development of atherosclerosis and targets for intervention against cardiovascular disease
title_short Apolipoproteins A-I and B: biosynthesis, role in the development of atherosclerosis and targets for intervention against cardiovascular disease
title_sort apolipoproteins a-i and b: biosynthesis, role in the development of atherosclerosis and targets for intervention against cardiovascular disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2291326/
https://www.ncbi.nlm.nih.gov/pubmed/17969379
work_keys_str_mv AT olofssonsvenolof apolipoproteinsaiandbbiosynthesisroleinthedevelopmentofatherosclerosisandtargetsforinterventionagainstcardiovasculardisease
AT wiklundolov apolipoproteinsaiandbbiosynthesisroleinthedevelopmentofatherosclerosisandtargetsforinterventionagainstcardiovasculardisease
AT borenjan apolipoproteinsaiandbbiosynthesisroleinthedevelopmentofatherosclerosisandtargetsforinterventionagainstcardiovasculardisease